

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended) An isolated polynucleotide comprising 150 contiguous nucleotides of nucleotides 1 to 11,407 of SEQ ID NO:1 ~~and having enhancer activity~~, wherein the 150 contiguous nucleotides are not depicted within SEQ ID NO:2 or SEQ ID NO:3 and said 150 contiguous nucleotides have prostate-specific enhancer activity.

2. (currently amended) The polynucleotide of claim 1, wherein said 150 contiguous nucleotides ~~comprises nucleotides~~ are found within nucleotides about 5976 to about 9620 of SEQ ID NO:1.

3. (currently amended) The polynucleotide of claim 1, wherein said 150 contiguous nucleotides ~~comprises nucleotides~~ are found within nucleotides about 6859 to about 8627 of SEQ ID NO:1.

4. (currently amended) The polynucleotide of claim 1, wherein said 150 contiguous nucleotides ~~comprises nucleotides~~ are found within nucleotides about 7200 to about 8371 of SEQ ID NO:1.

5. (currently amended) The polynucleotide of claim 1, wherein said 150 contiguous nucleotides ~~comprises nucleotides~~ are found within nucleotides about 8021 to about 8371 of SEQ ID NO:1.

6. (currently amended) An isolated polynucleotide comprising 150 contiguous nucleotides having at least about 70% sequence identity to a sequence within nucleotides 1 to 11,407 of SEQ ID NO:1, said polynucleotide having enhancer activity, wherein said 150 contiguous nucleotides are not depicted within SEQ ID NO:2 or SEQ ID NO:3 and said 150 contiguous nucleotides have prostate-specific enhancer activity.

7. (canceled)

8. (original) An isolated polynucleotide comprising nucleotides about 8021 to about 8371 of SEQ ID NO:1, wherein said polynucleotide has enhancer activity.

9. (original) An isolated polynucleotide of claim 8, wherein the polynucleotide comprises nucleotides about 7200 to about 8371 of SEQ ID NO:1, wherein said polynucleotide has enhancer activity.

10. (original) An isolated polynucleotide of claim 8, wherein the polynucleotide comprises nucleotides about 6859 to about 8627 of SEQ ID NO:1, wherein said polynucleotide has enhancer activity.

11. (original) An isolated polynucleotide of claim 8, wherein the polynucleotide comprises nucleotides about 5976 to about 9620 of SEQ ID NO:1, wherein said polynucleotide has enhancer activity.

12. (original) An isolated polynucleotide of claim 8, wherein the polynucleotide comprises nucleotides about 1 to about 9765 of SEQ ID NO:1, wherein said polynucleotide has enhancer activity.

13. (original) An isolated polynucleotide of claim 8, wherein the polynucleotide comprises nucleotides about 1 to about 11,407 of SEQ ID NO:1, wherein said polynucleotide has enhancer activity.

14-30 (canceled)

31. (currently amended) An adenovirus vector for selective cytolysis of a prostate target cell comprising an adenovirus gene essential for replication under transcriptional control of a human glandular kallikrein transcription regulatory element (*hKLK2*-TRE), wherein said *hKLK2*-TRE comprises a promoter and nucleotides about 8021 to about 8371 of SEQ ID NO:1.

32. (currently amended) The adenovirus vector of claim 31, wherein said adenovirus gene essential for adenoviral replication is selected from the group consisting of E1A, E1B, E2 and E4.

33-83 (canceled)